What Should Investors Know About Connect Biopharma (CNTB) Stock?

Small-cap health care company Connect Biopharma has moved -1.8% this evening, reaching $0.9 per share. In contrast, the average analyst target price for the stock is $6.99.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is based in the United States.

Make Sure to Consider the Following Before Buying Connect Biopharma:

  • Connect Biopharma has moved 21.1% over the last year.

  • CNTB has a forward P/E ratio of -0.4 based on its EPS guidance of -2.06.

  • Its Price to Book (P/B) ratio is 0.05

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.